Peregrine Capital Management LLC Corcept Therapeutics Inc Transaction History

Peregrine Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 17, 2020	SELL	$10.11 - $14.04 $3.92 Million - $5.44 Million	-387,602 Closed	0 $0
Q4 2019 Jan 16, 2020	SELL	$12.06 - $16.96 $10,757 - $15,128	-892 Reduced 0.23%	387,602 $4.69 Million
Q3 2019 Oct 16, 2019	SELL	$10.41 - $14.66 $932,205 - $1.31 Million	-89,549 Reduced 18.73%	388,494 $5.49 Million
Q2 2019 Jul 18, 2019	SELL	$9.78 - $12.76 $24,117 - $31,466	-2,466 Reduced 0.51%	478,043 $0
Q1 2019 Apr 12, 2019	SELL	$10.03 - $15.71 $18,575 - $29,094	-1,852 Reduced 0.38%	480,509 $0
Q4 2018 Jan 17, 2019	BUY	$11.29 - $17.19 $1.81 Million - $2.76 Million	160,562 Added 49.9%	482,361 $6.44 Million
Q3 2018 Oct 18, 2018	BUY	$12.27 - $15.65 $3.95 Million - $5.04 Million	321,799 New	321,799 $0

311

88.3M

1.07M

973K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $4.95B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.